ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2017
Performance of [
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population.Alzheimer's research & therapy · 2021Pooled it
- Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Pooled it
- A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2018Pooled it
- Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.Acta neuropathologica communications · 2019Trial
- From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment.European journal of nuclear medicine and molecular imaging · 2026Article
- Tau PET imaging as a mediator between glymphatic dysfunction and cognitive decline: a cross-sectional and longitudinal study.European journal of nuclear medicine and molecular imaging · 2026Article
- Concordance between amyloid PET and CSF biomarkers in clinical setting: a cross-platform comparison and in-depth analysis of discordant cases.Scientific reports · 2025Article
- Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies.AJNR. American journal of neuroradiology · 2025Review
- Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Observational
- Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- Development and Validation of aJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable.The journal of prevention of Alzheimer's disease · 2025Article
- Ultra-fast [EJNMMI physics · 2024Article
- Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The use of neuroimaging techniques in the early and differential diagnosis of dementia.Molecular psychiatry · 2023Review
- Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits.International journal of molecular sciences · 2023Review
- FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer's Disease: Benefits and Pitfalls.Diagnostics (Basel, Switzerland) · 2023Article
- Software compatibility analysis for quantitative measures of [EJNMMI research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPerformance of the amyloid tracer [
methodsAfter [
resultsBy SoT, sensitivity and specificity of majority image interpretations were, respectively, 91.9% and 87.5% with "original CERAD," 90.8% and 90.0% with "modified CERAD," and 85.7% and 100% with the 2012 NIA-AA criteria. DISCUSSION: The high accuracy of either CERAD criteria suggests that [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.